Cargando…

“Direct to Drug” screening as a precision medicine tool in multiple myeloma

Seventy-six FDA-approved oncology drugs and emerging therapeutics were evaluated in 25 multiple myeloma (MM) and 15 non-Hodgkin’s lymphoma cell lines and in 113 primary MM samples. Ex vivo drug sensitivities were mined for associations with clinical phenotype, cytogenetic, genetic mutation, and tran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonolo de Campos, Cecilia, Meurice, Nathalie, Petit, Joachim L., Polito, Alysia N., Zhu, Yuan Xiao, Wang, Panwen, Bruins, Laura A., Wang, Xuewei, Lopez Armenta, Ilsel D., Darvish, Susie A., Ahmann, Greg J., Henderson, Kimberly J., Tian, Shulan, Kruse, Jonas J., Stewart, William M., Larsen, Jeremy T., Reeder, Craig B., Dingli, David, Kapoor, Prashant, Kumar, Shaji K., Fonseca, Rafael, Bergsagel, P. Leif, Braggio, Esteban, Stewart, A. Keith
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214452/ https://www.ncbi.nlm.nih.gov/pubmed/32393731 http://dx.doi.org/10.1038/s41408-020-0320-7

Ejemplares similares

Identification of PIKfyve kinase as a target in multiple myeloma
por: de Campos, Cecilia Bonolo, et al.
Publicado: (2020)

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4
por: Zhu, Yuan Xiao, et al.
Publicado: (2019)

Transcriptional profiles define drug refractory disease in myeloma
por: Zhu, Yuan Xiao, et al.
Publicado: (2022)

Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients
por: Kortuem, K M, et al.
Publicado: (2016)

Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
por: Bansal, Radhika, et al.
Publicado: (2023)

Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms
por: Gagnon, Marie-France, et al.
Publicado: (2022)

Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells
por: Kumar, Harish, et al.
Publicado: (2022)

Phase 2 trial of Intravenously Administered Plerixafor for Stem Cell Mobilization in Patients with Multiple Myeloma Following Lenalidomide Based Initial Therapy
por: Kumar, Shaji K., et al.
Publicado: (2013)

Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma
por: Jain, Tania, et al.
Publicado: (2017)

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma
por: Kumar, Shaji K., et al.
Publicado: (2018)

Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients
por: Rajkumar, S, et al.
Publicado: (2023)

Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma
por: Ravi, Praful, et al.
Publicado: (2018)

Lessons from next-generation sequencing analysis in hematological malignancies
por: Braggio, E, et al.
Publicado: (2013)

MYC dysregulation in the progression of multiple myeloma
por: Misund, K, et al.
Publicado: (2019)

Walter Michael Kuehl, MD - October 25, 1939 - April 30, 2023
por: Bergsagel, Leif
Publicado: (2023)

Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma
por: Smadbeck, James, et al.
Publicado: (2019)

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
por: Rosenthal, A, et al.
Publicado: (2016)

Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies
por: Kumar, Shaji, et al.
Publicado: (2019)

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma
por: Miller, A, et al.
Publicado: (2017)

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement
por: Gonsalves, Wilson I., et al.
Publicado: (2018)

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
por: Fonseca, Rodrigo, et al.
Publicado: (2023)

Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
por: Fonseca, Rodrigo, et al.
Publicado: (2023)

Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant
por: Meermeier, Erin W., et al.
Publicado: (2023)

Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup
por: Wiedmeier-Nutor, Julia Erin, et al.
Publicado: (2022)

Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial
por: Reeder, Craig B., et al.
Publicado: (2009)

Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response
por: Abdallah, Nadine, et al.
Publicado: (2020)

Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation
por: Roy, V, et al.
Publicado: (2015)

UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression
por: Hussain, Sajjad, et al.
Publicado: (2015)

Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry
por: Baughn, Linda B., et al.
Publicado: (2018)

Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma
por: Baughn, Linda B., et al.
Publicado: (2023)

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma
por: Ravi, P, et al.
Publicado: (2017)

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
por: Kumar, S K, et al.
Publicado: (2015)

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma
por: Ravi, P, et al.
Publicado: (2016)

A simple additive staging system for newly diagnosed multiple myeloma
por: Abdallah, Nadine H., et al.
Publicado: (2022)

Multipeptide stimulated PBMCs generate T(EM)/T(CM) for adoptive cell therapy in multiple myeloma
por: Vardam-Kaur, Trupti, et al.
Publicado: (2021)

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies
por: Bogenberger, J M, et al.
Publicado: (2014)

Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
por: Muchtar, Eli, et al.
Publicado: (2022)

The Impact of Diabetes and Associated Cardiometabolic Risk Factors on Members: Strategies for Optimizing Outcomes
por: Hoerger, Thomas J., et al.
Publicado: (2008)

Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups
por: Asmann, Yan W., et al.
Publicado: (2021)

Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL
por: Griffin, Rosalie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nq6u87d3m27irfp5u2dpss2s4e